Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477074 | 0.86 | CES2 (0.33) | POLBTSHRALDH1A1 | |
| SCHEMBL6477069 | 0.82 | S1PR3 (0.39) | PTGER4S1PR3P2RX7KDM4EMAPK1 | |
| SCHEMBL6477108 | 0.81 | PTGER4 (0.39) | PTGER4MAPTS1PR3P2RX7HTT | |
| SCHEMBL6477071 | 0.81 | PTGER4 (0.38) | PTGER4MAPTS1PR3P2RX7HTT | |
| SCHEMBL7064689 | 0.77 | KLKB1 (0.41) | S1PR3 | |
| SCHEMBL6818974 | 0.75 | S1PR3 (0.35) | PTGER4S1PR3KDM4EMAPK1RAB9A | |
| SCHEMBL7063737 | 0.75 | KLKB1 (0.39) | S1PR3 | |
| SCHEMBL8334774 | 0.73 | CYP2C19 (0.42) | KDM4EMAPK1HSD17B10CYP1A2CYP2D6 | |
| SCHEMBL6814257 | 0.73 | NAMPT (0.39) | S1PR3KDM4EMAPK1SMN1; SMN2HSD17B10 | |
| SCHEMBL6289363 | 0.72 | KDM4E (0.43) | PTGER4S1PR3KDM4EMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | claimed |
| US-6897223-B2 | Pyridine fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040063673-A1 | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors | JOHNSON ADAM RICHARD (US) | 2004-04-01 | — | — | US | disclosed |
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014384-A2 | CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014908-A1 | HETEROBICYLCIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063673-A1 | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors | MMP13, MMP1, MMP11 | PTGER4 1448/4885MAPT 2540/4885S1PR3 304/4885 |
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | PTGER4 889/4885MAPT 4485/4885S1PR3 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.